Skip to content

On the Cyberknife Dose Fraction of Liver Cancer Treatment

On the Cyberknife Dose Fraction of Liver Cancer Treatment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03295500
Enrollment
657
Registered
2017-09-28
Start date
2017-11-01
Completion date
2021-09-24
Last updated
2021-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CyberKnife Radiosurgery

Keywords

CyberKnife, hepatocellular, dose fraction, ICG R15

Brief summary

The research aims to the primary hepatic carcinoma patients whose diameter of the single tumor is equal or less than 5cm.By supervising the changes of liver function, Child-Pugh score, ICG-R15 value, secondary reaction, incidence rate of RILD during and after the radiotherapy, meanwhile combining the outcome of the progression of disease and the condition of survival quality, the optimum proposal could be obtained and apply to clinic thus make the treatment safe, effective and personalized.

Interventions

RADIATIONDose fraction forms

The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.

Sponsors

Beijing 302 Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* The participants are from 30 to 80 years of age, without gender restriction * With the hepatopathy background, the diagnosis of primary hepatic carcinoma is confirmed by image examination and laboratory test(the diagnosis criteria is according to the primary hepatic carcinoma rule of diagnosis and treat in 2007) * The max diameter of single tumor ≤5cm * Child-Pugh Classification(CPC) A or B * ECOG score 0 or 1 * Leukocyte is more than 2×109/L and thrombocyte is more than 60×109/L * Kidney function is normal * Unsuitable or rejecting other therapies such as resection, liver transplantation etc * Anticipated lifetime is longer than six months * The participants who are voluntary comply with the requirements of research * The participants agree to sign the informed consent.

Exclusion criteria

* The metastasis occur outside of liver * Child-Pugh Classification(CPC) * The outline of tumor is not confirmed by image examination * With hepatic or any other abdomen radiotherapy history before * With severe internal medicine diseases * Bone marrow haematopoietic function or kidney function is severe failure * Intractable ascites * The position of tumor is nearby esophagus, stomach or intestine * The normal liver volume less than 700 cm3

Design outcomes

Primary

MeasureTime frameDescription
Local control rateFrom date of the participants completing the therapy until the date of first documented progression, assessed up to 36 months.Local control illustrates the time from the tumor appearance to progress (the diameter more than or equal to 1.5 times of original) .The ratio of the number of the local control patients to the whole number of patients is local control rate.
Overall survival rateFrom date of the participants diagnosed until the date of death from any cause, assessed up to 36 months.Overall survival rate means the ratio of the number of patients who are alive to the whole patients after the treatment.

Secondary

MeasureTime frameDescription
RILD rateFrom the date of radiotherapy completion until the 4 months after therapy,up to 6 months.the rate of radiotherapy induced liver disease
Child-Pugh scoreFrom the date of radiotherapy completion until the 4 months after therapy,up to 6 months.By testing the liver function,coagulation function and ascites,we could calculate the Child-Pugh score,which reflect the liver function roundly.
the value of ICG R15From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.It means the indocyanine green retention rate at 15 minutes,which reflects the liver reserve.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026